Monday, November 7, 2016

BRIEF-Biogen and Ionis Pharmaceuticals announce SPINRAZA meets primary endpoint at interim analysis of phase 3 cherish study

* Biogen and Ionis Pharmaceuticals announce SPINRAZA

(nusinersen) meets primary endpoint at interim analysis of phase

3 cherish study in later-onset spinal muscular atrophy

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)